Regulation of genes in the arachidonic acid metabolic pathway by RNA processing and RNA-mediated mechanisms

Wiley Interdisciplinary Reviews: RNA

Volumn 4, Issue 5, 2013, Pages 593-605

  Lutz, Carol S ^a   Cornett, Ashley L ^a  

^a The State University of New Jersey   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONIC ACID; CLEAVAGE AND POLYADENYLATION SPECIFICITY FACTOR; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; MESSENGER RNA; MICRORNA 101; MICRORNA 146A; MICRORNA 16; POLYADENYLIC ACID; RNA; TRANS ACTING FACTOR;

3' UNTRANSLATED REGION; ALTERNATIVE RNA SPLICING; ARACHIDONIC ACID METABOLISM; AU RICH ELEMENT; BINDING SITE; CELL PROLIFERATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CODON; CONSENSUS SEQUENCE; EXON; FIBROBLAST; GENE EXPRESSION REGULATION; GENETIC REGULATION; GENETIC VARIABILITY; GLIOBLASTOMA; HERPES SIMPLEX VIRUS 1; HUMAN; INTRON; METABOLIC REGULATION; NONHUMAN; NONSENSE MEDIATED MRNA DECAY; POLYADENYLATION; PREMATURE TERMINATION CODON; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN RNA BINDING; PROTEOMICS; REVIEW; RNA PROCESSING; RNA STABILITY; SIGNAL TRANSDUCTION; TRANSCRIPTOMICS;

5-LIPOXYGENASE-ACTIVATING PROTEINS; ARACHIDONATE 5-LIPOXYGENASE; ARACHIDONIC ACID; EICOSANOIDS; GENE EXPRESSION REGULATION; HUMANS; METABOLIC NETWORKS AND PATHWAYS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RNA PROCESSING, POST-TRANSCRIPTIONAL; TRANSCRIPTION, GENETIC;

EID: 84882273602     PISSN: 17577004     EISSN: 17577012     Source Type: Journal    
DOI: 10.1002/wrna.1183     Document Type: Review

References (120)

1. Hla T, Bishop-Bailey D, Liu CH, Schaefers HJ, Trifan OC. Cyclooxygenase-1 and -2 isoenzymes. Int J Biochem Cell Biol 1999, 31:551-557.
2. Vane JR, Botting RM. New insights into the mode of action of anti-inflammatory drugs. Inflamm Res 1995, 44:1-10.
3. Mitchell JA, Larkin S, Wiliams TJ. Cyclooxygenase-2: regulation and relevance in inflammation. Biochem Pharmacol 1995, 50:1535-1542.
4. Hla T, Farrell M, Kumar A, Bailey JM. Isolation of the cDNA for human prostaglandin H synthase. Prostaglandins 1986, 32:829-845.
5. DeWitt DL, Smith WL. Primary structure of prostaglandin G/H synthase from sheep vesicular gland determine from complementary DNA sequence. Proc Natl Acad Sci USA 1998, 85:1412-1416.
6. Merlie JP, Fagan D, Mudd J, Needleman P. Isolation and characterization of the complementary DNA for sheep seminal vesicle prostaglandin endoperoxidase synthase (cyclooxygenase). J Biol Chem 1988, 263:3550-3553.
7. Xie W, Cipman JG, Robertson DL, Erikson RL, Simmons DL. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci USA 1991, 88:2692-2696.
8. O'Banion MK, Winn VD, Yong DA. cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase. Proc Natl Acad Sci USA 1992, 89:4888-4892.
9. Hla T, Neilson K. Human cyclooxygenase-2 cDNA. Proc Natl Acad Sci USA 1992, 89:7384-7388.
10. Garavito R, Mulchiak A. The structure of mammalian cyclooxygenases. Annu Rev Biomol Struct 2002, 32:183-206.
11. Chandrasekharan NV, Dai H, Roos KLT, Evanson NK, Tomsik J, Elton TS, Simmons DL. COX-3, a cyclooxygenase-1 variant inhibited by acetominophen and other analgesic/antipyretic drugs: cloning, structure and expression. Proc Natl Acad Sci USA 2002, 99:13926-13931.
12. Hla T, Maciag T. Cyclooxygenase gene expression is down-regulated by heparin-binding (acidic fibroblast) growth factor-1 in human endothelial cells. J Biol Chem 1991, 266:24059-24063.
13. Ristimaki A, Garfinkel S, Wessendorf J, Maciag T, Hal T. Induction of cyclooxygenase-2 by interleukin-1 α. Evidence for post-transcriptional regulation. J Biol Chem 1994, 269:11769-11775.
14. O'Banion MK, Miller JC, Chang JW, Kaplan MD, Coleman PD. Interleukin-1 β indices prostaglandin G/H synthase (cyclooxygenase-2) in primary murine astrocyte cultures. J Neurochem 1996, 66:2532-2540.
15. Bazan NG, Fletcher BS, Herschmann HR, Mukherjee PK. Platelet-activating factor and retinoic acid synergistically activate the inducible prostaglandin synthase gene. Proc Natl Acad Sci USA 1994, 91:5252-5256.
16. Hla T, Ristimaki A, Appleby S, Barriocanal JG. Cyclooxygenase gene expression in inflammation and angiogenesis. Ann N Y Acad Sci 1993, 696:197-204.
17. Williams CS, Mann M, DuBois RN. The role of cyclooxygenases in inflammation, cancer and development. Oncogene 1999, 18:7908-7916.
18. Prescott SM. Is cyclooxygenase-2 the α and omega in cancer? J Clin Invest 2000, 105:1511-1513.
19. Prescott SM, Fitzpatrick FA. Cyclooxygenase and carcinogenesis. Biochim Biophys Acta 2000, 1470:69-78.
20. Bazan NG. COX-2 as a multifunctional neuronal modulator. Nat Med 2001, 7:414-415.
21. Bishop-Bailey D, Calatayud S, Warner TD, Hla T, Mitchell JA. Prostaglandins and the regulation of tumor growth. J Environ Pathol Toxicol Oncol 2002, 21:93-101.
22. Meagher EA. Cardiovascular and renovascular implications of COX-2 inhibition. Curr Pharm Des 2004, 10:603.
23. Zidar N, Dolenc-Strazar Z, Jeruc J, Jerse M, Balazic J, Gartner U, Jermol U, Zupanc T, Stajer D. Expression of cyclooxygenase-1 and cyclooxygenase-2 in the normal human heart and in myocardial infarction. Cardiovasc Pathol 2007, 16:300-304.
24. Lovgren AK, Janis LA, Hartney JM, Parsons KK, Audoly LP, FitzGerald GA, Tilley SL, Koller BH. COX-2 derived prostacyclin protects against bleomycin-induced pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2006, 291:L144-L156.
25. Ochiai M, Oguri T, Isobe T, Ishika S, Yamakido M. Cyclooxygenase-2 (COX-2) mRNA expression levels in normal lung tissues and non-small cell lung cancers. Cancer Sci 2005, 90:1338-1373.
26. Clayton A, Knox AJ. COX-2: a link between airway inflammation and disordered chloride secretion in cystic fibrosis? Thorax 2006, 61:552-553.
27. Kuwano T, Nakao S, Yamamoto H, Tsuneyoshi M, Yamamoto T, Kuwano M, Ono M. Cyclooxygenase 2 is a key enzyme for inflammatory cytokine-induced angiogenesis. FASEB J 2004, 18:300-310.
28. Rodrigues-Artalejo F, Guallat-Castillon P, Banegas Banegas JR, Gutierrez-Fisac JL, del Rey CJ. The association between mortality from ischaemic heart disease and mortality from leading chronic diseases. Eur Heart J 2000, 21:1841-1852.
29. Sin DD, Wu LL, Man SFP. The relationship between reduced lung function and cardiovascular mortality. Chest 2005, 127:1952-1959.
30. Pope CA, Burnett RT, Thurston GD, Thun MJ, Calle EE, Kewski D, Godleski JJ. Cardiovascular mortality and long term exposure to particulate air pollution: epidemiological evidence of general pathophysiological pathways of disease. Circulation 2004, 109:71-77.
31. McGeer PL, McGeer EG, Yasojima K. Expression of COX-1 and COX-2 mRNAs in atherosclerotic plaques. Exp Gerontol 2002, 37:925-929.
32. Abbate A, Santini D, Biondi-Zoccai GGL, Scarpa S, Vasaturo F, Liuzzo G, Bussani R, Silvestri F, Baldi F, Crea F, et al. Cyclooxygenase-2 (COX-2) expression at the site of recent myocardial infarction: friend or foe? Heart 2004, 90:440-443.
33. FitzGerald GA. COX-2 and beyond: approaches to prostaglandin inhibition in human disease. Nat Rev Drug Discov 2003, 2:879-890.
34. Grosser T, Fries S, FitzGerald GA. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest 2006, 116:4-15.
35. Chen CC, Sun YT, Chen JJ, Chiu KT. TNF-α induced cyclooxygenase-2 expression in human lung epithelial cells: involvement of the phospholipase C-gamma 2, protein kinase C-α, tyrosine kinase, NJ-kappaB-inducing kinase, and I-kappaB kinase 1/2 pathway. J Immunol 2000, 165:2719-2728.
36. Duffield-Lillico AJ, Boyle JO, Zhou XK, Ghosh A, Butala GS, Subbaramaiah K, Newman RA, Morrow JD, Milne GL, Dannenberg AJ. Levels of prostaglandin E metabolite and leukotriene E(4) are increased in the urine of smokers: evidence that celecoxib shunts arachidonic acid into the 5-lipoxygenase pathway. Cancer Prev Res 2009, 2:322-329.
37. Spira A, Beane JE, Shah V, Steiling K, Liu G, Schembri F, Gilman S, Dumas YM, Calner P, Sebastiani P, et al. Airway epithelial gene expression in the diagnostic evaluation of smokers who suspect lung cancer. Nat Med 2007, 13:361-366.
38. Herb F, Thye T, Niemann S, Browne EN, Chinbuah MA, Gyapong J, Osei I, Owusu-Dabo E, Werz O, Rüsch-Gerdes S, et al. ALOX5 variants associated with susceptibility to human pulmonary tuberculosis. Hum Mol Genet 2008, 17:1052-1060.
39. Hall-Pogar T, Zhang H, Tian B, Lutz CS. Alternative polyadenylation of cyclooxygenase-2. Nucleic Acids Res 2005, 33:2565-2579.
40. Hall-Pogar T, Liang S, Hague LK, Lutz CS. Specific trans-acting proteins interact with auxiliary RNA polyadenylation elements in the COX-2 3′ UTR. RNA 2007, 13:1103.
41. Vane JR. Inhibition of prostaglandin biosynthesis as a mechanism of action of aspirin-like drugs. Nat New Biol 1971, 231:232-235.
42. Sørensen HT, Mellemkjær L, Blot WJ, Nielsen GL, Steffensen FH, et al. Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin. Am J Gastroenterol 2000, 95:2218-2224.
43. Kujubu DA, Fletcher BS, Varnum BC, Lim RW, Herschman HR. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J Biol Chem 1991, 266:12866-12872.
44. Tanabe T, Tohnai N. Cyclooxygenase isozymes and their gene structures and expression. Prostaglandins Other Lipid Mediat 2002, 68-69:95-114.
45. Epstein M. Cardiovascular and renal effects of COX-2-specific inhibitors: recent insights and evolving clinical implications. Am J Ther 2001, 8:81-83.
46. Graham DJ, Campen D, Hui R, Spence M, Cheetham C, Levy G, Shoor S, Ray WA. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 2005, 365:475-481.
47. Maniatis T, Reed R. An extensive network of coupling among gene expression machines. Nature 2002, 416:499-506.
48. Proudfoot NJ, Furger A, Dye MJ. Integrating mRNA processing with transcription. Cell 2002, 108:501-512.
49. Proudfoot NJ. Ending the message: poly(A) signals then and now. Genes Dev 2011, 25:1770-1782.
50. Zhao J, Hyman L, Moore C. Formation of mRNA 3′ ends in eukaryotes: mechanism, regulation and interrelationships with other steps in mRNA synthesis. Microbiol Mol Biol Rev 1999, 63:405-445.
51. Lewis J, Gunderson S, Mattaj IW. The influence of 5′ and 3′ end structures on pre-mRNA metabolism. J Cell Sci Suppl 1995, 19:13-19.
52. Jacobson A, Peltz SW. Interrelationships of the pathways of mRNA decay and translation in eukaryotic cells. Annu Rev Biochem 1996, 65:693-739.
53. Sachs AB, Sarnow P, Hentze MW. Starting at the beginning, middle and end: translation initiation in eukaryotes. Cell 1997, 89:831-838.
54. Wickens M, Anderson P, Jackson RJ. Life and death in the cytoplasm: messages from the 3′ end. Curr Opin Genet Dev 1997, 7:220-232.
55. Colgan DF, Manley JL. Mechanism and regulation of mRNA polyadenylation. Genes Dev 1997, 11:2755-2766.
56. Manley JL. A complex protein assembly catalyzes polyadenylation of mRNA precursors. Curr Opin Genet Dev 1995, 5:222-228.
57. Wahle E. 3′ end cleavage and polyadenylation of mRNA precursors. Biochim Biophys Acta 1995, 1261:183-194.
58. Wahle E, Keller W. The biochemistry of polyadenylation. Trends Biochem Sci 1996, 21:247-250.
59. Proudfoot N. Ending the message is not so simple. Cell 1996, 87:779-781.
60. Keller W, Minvielle-Sebastia L. A comparison of mammalian and yeast pre-mRNA 3′ end processing. Curr Opin Cell Biol 1997, 9:329-336.
61. Wahle E, Kuhn U. The mechanism of 3′ cleavage and polyadenylation of eukaryotic pre-mRNA. Prog Nucleic Acids Res Mol Biol 1997, 57:41-71.
62. Edmonds M. A history of poly(A) sequences: from formation to factors to function. Prog Nucleic Acids Res Mol Biol 2002, 71:285-389.
63. Ryan K, Calvo O, Manley JL. Evidence that polyadenylation factor CPSF-73 is the mRNA 3′ processing endonuclease. RNA 2004, 10:565-573.
64. Edwalds-Gilbert G, Prescott J, Falck-Pederson E. 3′ RNA processing efficiency plays a primary role in generating termination-competent RNA polymerase II elongation complexes. Mol Cell Biol 1993, 13:3472-3480.
65. Moreira A, Lutz CS. Alternative polyadenylation in eukaryotes: an effective regulator of gene expression. WIREs RNA 2011, 2:22-31.
66. Mayr C, Bartel DP. Widespread shortening of 3′UTRs by alternative cleavage and polyadenylation activates oncogenes in cancer cells. Cell 2009, 138:673-684.
67. Di Giammartino DC, Nishida K, Manley JL. Mechanisms and consequences of alternative polyadenylation. Mol Cell 2011, 43:853-866.
68. Tian B, Hu H, Zhang H, Lutz CS. A large-scale analysis of mRNA polyadenylation of human and mouse genes. Nucleic Acids Res 2005, 33:201-212.
69. Zlotorynski E, Agami R. A PASport to cellular proliferation. Cell 2008, 134:208-210.
70. Sandberg R, Neilson JR, Sarma A, Sharp PA, Burge CB. Proliferating cells express mRNAs with shortened 3′ untranslated regions and fewer microRNA target sites. Science 2008, 320:1643-1647.
71. Chabot B. Directing alternative splicing: cast and scenarios. Trends Genet 1996, 12:472-478.
72. Pan Q, Shai O, Lee LJ, Frey BJ, Blencowe BJ. Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. Nat Genet 2008, 40:1413-1415.
73. Leparc GG, Mitra RD. A sensitive procedure to detect alternatively spliced mRNA in pooled-tissue samples. Nucleic Acids Res 2007, 35:e146.
74. Matlin AJ, Clark F, Smith CWJ. Understanding alternative splicing: towards a cellular code. Nat Rev 2005, 6:386-398.
75. Wang Z, Burge CB. Splicing regulation: from a parts list of regulatory elements to an integrated splicing code. RNA 2008, 14:802-813.
76. Hla T. Molecular characterization of the 5.2 KB isoform of the human cyclooxygenase-1 transcript. Prostaglandins 1996, 51:81-85.
77. Cornett AL, Lutz CS. 2013. Regulation of COX-2 expression in lung cancer cells. Manuscript in preparation.
78. Plant MH, Laneuville O. Characterization of a novel transcript of prostaglandin endoperoxide H synthase 1 with a tissue-specific profile of expression. Biochem J 1999, 344:677-685.
79. Roos KLT, Simmons DL. Cyclooxygenase variants: the role of alternative splicing. Biochem Biophys Res Commun 2005, 338:62-69.
80. Ochs MJ, Sorg BL, Pufahl L, Grez M, Suess B, Steinhilber D. Post-transcriptional regulation of 5-lipoxygenase mRNA expression via alternative splicing and nonsense mediated mRNA decay. PLoS One 2012, 7:e31363.
81. Boudreau LH, Bertin J, Robichaud PP, Laflamme M, Ouellette RJ, Flamand N, Surette ME. Novel 5-lipoxygenase isoforms affect the biosynthesis of 5-lipoxygenase products. FASEB J 2011, 25:1097-1105.
82. Dehlin E, Wormington M, Korner CG, Wahle E. Cap-dependent deadenylation of mRNA. EMBO J 2000, 19:1079-1086.
83. Gao M, Fritz DT, Ford LP, Wilusz J. Interaction between a poly(A)-specific ribonuclease and the 5′ cap influences mRNA deadenylation rates in vitro. Mol Cell 2000, 5:479-488.
84. Gao M, Wilusz CJ, Peltz SW, Wilusz J. A novel mRNA-decapping activity in HeLa cytoplasmic extracts is regulated by AU-rich elements. EMBO J 2001, 20:1134-1143.
85. Chen CY, Shyu AB. Mechanisms of deadenylation-dependent decay. WIREs RNA 2011, 2:167-183.
86. Barreau C, Paillard L, Osborne HB. AU-rich elements and associated factors: are there unifying principles? Nucleic Acids Res 2006, 22:7138-7150.
87. Fan XC, Steitz JA. Overexpression of HuR, a nuclear-cytoplasmic shuttling protein, increases the in vivo stability of ARE-containing mRNAs. EMBO J 1998, 17:3448-3460.
88. Ford LP, Watson J, Keene JD, Wilusz J. ELAV proteins stabilize deadenylated intermediates in a novel in vitro mRNA deadenylation/degredation system. Genes Dev 1999, 13:188-201.
89. Peng SS, Chen CY, Xu N, Shyu AB. RNA stabilization by the AU-rich element binding protein, HuR, an ELAV protein. EMBO J 1998, 17:3461-3470.
90. Lai WS, Carballo E, Strum JR, Kennington EA, Phillips RS, Blackshear PJ. Evidence that tristetraprolin binds to AU-rich elements and promotes the deadenylation and destabilization of tumor necrosis factor α mRNA. Mol Cell Biol 1991, 19:4311-4323.
91. Loflin P, Chen CY, Shyu AB. Unraveling a cytoplasmic role for hnRNPD in the in vivo mRNA destabilization directed by the AU-rich element. Genes Dev 1999, 13:1884-1897.
92. Mukherjee D, Gao M, O'Connor JP, Raijmakers R, Pruijn G, Lutz CS, Wilusz J. The mammalian exosome mediates the efficient degradation of mRNA that contain AU-rich elements. EMBO J 2002, 21:165-174.
93. Chen CY, Gherzi R, Ong SE, Chan EL, Raijmakers R, Pruijn GJ, Stoecklin G, Moroni C, Mann M, Karin M. AU binding proteins recruit the exosome to degrade ARE-containing mRNAs. Cell 2001, 107:451-464.
94. Gou Q, Liu CH, Ben-Av P, Hla T. Dissociation of basal turnover and cytokine-induced transcript stabilization of the human cyclooxygenase-2 mRNA by mutagenesis of the 3′ untranslated region. Biochem Biophys Res Commun 1998, 242:508-512.
95. Dixon DA, Kaplan CD, McIntyre TM, Zimmerman GA, Prescott SM. Post-transcriptional control of cyclooxygenase gene expression. J Biol Chem 2000, 275:11750-11757.
96. Cok SJ, Acton SJ, Morrison AR. The proximal region of the 3′ untranslated region of cyclooxygenase-2 is recognized by a multimeric protein complex containing HuR, TIA-1, TIAR and the heterogenous nuclear ribonucleoprotein U. J Biol Chem 2003, 278:36157-36162.
97. Mukhopadhyay D, Houchen CW, Kennedy S, Dieckgraefe BK, Anant S. Coupled mRNA stabilization and translational silencing of cyclooxygenase-2 by a novel RNA binding protein, CUGBP2. Mol Cell 2003, 11:113-126.
98. Dixon DA, Tolley ND, King PH, Nabors LB, McIntyre TM, Zimmerman GA, Prescott SM. Altered expression of the mRNA stability factor HuR promotes cyclooxygenase-2 expression in colon cancer cells. J Clin Invest 2001, 108:1657-1665.
99. Harper KA, Tyson-Capper AJ. Complexity of COX-2 gene regulation. Biochem Soc Trans 2008, 36:543-545.
100. Kishor A, Tandukar B, Ly YV, Toth EA, Suarez Y, Brewer G, Wilson GM. HSP70 is a novel posttranscriptional regulator of gene expression that binds and stabilizes selected mRNAs containing AU-rich elements. Mol Cell Biol 2013, 33:71-84.
101. Sully G, Dean JLE, Wait R, Rawlinson L, Santalucia T, Saklatvala J, Clark AR. Structural and functional dissection of a conserved destabilizing element of cyclo-oxygenase-2 mRNA: evidence against the involvement of AUF-1, AUF-2, tristetraprolin, HuR, or FBP1. Biochem J 2004, 377:629-639.
102. Maroney PA, Yu Y, Fisher J, Nilsen TW. Evidence that microRNAs are associated with translating messenger RNAs in human cells. Nat Struct Mol Biol 2006, 13:1102-1107.
103. Cheng AM, Byrom MW, Shelton J, Ford LP. Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis. Nucleic Acids Res 2005, 33:1290-1297.
104. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001, 411:494-498.
105. Landgraf P, Rusu M, Sheridan R, Sewer A, Iovino N, Aravin A, Pfeffer S, Rice A, Kamphorst AO, Landthaler M, et al. A mammalian microRNA expression atlas based on small RNA library sequencing. Cell 2007, 129:1401.
106. Chakrabarty A, Tranguch S, Daikoku T, Jensen K, Furneaux H, Dey SK. MicroRNA regulation of cyclooxygenase-2 during embryo implantation. PNAS 2007, 104:15144-15149.
107. Legendre M, Ritchie W, Lopez F, Gautheret D. Differential repression of alternative transcripts: a screen for miRNA targets. PLoS Comput Biol 2006, 2:0333-0342.
108. Suarez Y, Wang C, Manes TD, Pober JS. Cutting edge: TNF-induced microRNAs regulared TNF-induced expression of E-selectin and intercellular adhesion molecule-1 on human endothelial cells: feedback control of inflammation. J Immunol 2010, 184:21-25.
109. Urbich C, Kuehbacher A, Dimmeler S. Role of microRNAs in vascular disease, inflammation and angiogenesis. Cardiovasc Res 2008, 79:581-588.
110. Ochs MJ, Steinhilber D, Suess B. MicroRNA involved in inflammation: control of eicosanoid pathway. Front Pharmacol 2011, 2:1-6.
111. Strillacci A, Griffoni C, Sansone P, Paterini P, Piazzi G, Lazzarini G, Spisni E, Pantaleo MA, Biasco G, Tomasi V. MiR-101 downregulation is involved in cyclooxygenase-2 overexpression in human colon cancer cells. Exp Cell Res 2009, 315:1439-1447.
112. Tanaka T, Haneda S, Imakawa K, Sakai S, Nagaoka K. A microRNA, miR-101a, controls mammary gland development by regulating cyclooxygenase-2 expression. Differentiation 2009, 77:181-187.
113. Hiroki E, Akahira J, Suzuki F, Nagase S, Ito K, Suzuki T, Sasano H, Yaegashi N. Changes in microRNA expression levels correlate with clinicopathological features and prognoses in endometrial serous adenocarcinoma. Cancer Sci 2010, 101:241-249.
114. Ji Y, He Y, Liu L, Zhong X. MiRNA-26b regulates the expression of cyclooxygenase-2 in desferrioxamine-treated CNE cells. FEBS Lett 2010, 584:961-967.
115. Young LE, Moore AE, Sokol L, Meisner-Kober N, Dixon DA. The mRNA stability factor HuR inhibits microRNA-16 targeting of COX-2. Mol Cancer Res 2012, 10:167-180.
116. Jing Q, Huang S, Guth S, Zarubin T, Motoyama A, Chen J, Di Padova F, Lin SC, Gram H, Han J. Involvement of microRNA in AU-rich element-mediated mRNA stability. Cell 2005, 120:623-634.
117. Chen L, Wang X, Wang H, Li Y, Yan W, Han L, Zhang K, Zhang J, Wang Y, Feng Y, et al. miR-137 is frequently down-regulated in glioblastoma and is a negative regulator of Cox-2. Eur J Cancer 2012, 48:3104-3111.
118. Sato T, Liu X, Nelson A, Nakanishi M, Kanaji N, Wang X, Kim M, Li Y, Sun J, Michalski J, et al. Reduced miR-146a increase prostaglandin E2 in chronic obstructive pulmonary disease fibroblasts. Am J Respir Crit Care Med 2010, 182:1020-1029.
119. Hill JM, Zhao Y, Clement C, Neumann DM, Lukiw WJ. HSV-1 infection of human brain cells induces miR146a and Alzheimer-type inflammatory signaling. Neuroreport 2009, 20:1500-1505.
120. Gonsalves CS, Kalra VK. Hypoxia-mediated expression of 5-lipoxygenase-activating protein involves HIF-1 α and NF-kappaB and microRNAs 135a and 199a-5p. J Immunol 2010, 184:3878-3888.